Rx Product News

Published Online: Tuesday, September 10, 2013
Follow Pharmacy_Times:


Astagraf XL
Marketed by:
Astellas Pharma US, Inc
Indication: The FDA has approved Astagraf XL (tacrolimus extended-release capsules), a calcineurin-inhibitor immunosuppressant, for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab induction. The recommended dose with basiliximab induction is 0.15 mg/kg/day. Without basiliximab induction, the preoperative dose is 0.1 mg/kg/day and the postoperative dose is 0.2 mg/kg/day. Astagraf XL is not interchangeable with tacrolimus immediate-release capsules and should not be used simultaneously with cyclosporine.
Dosage Form: Capsules: 0.5, 1, and 5 mg
For More Information: www.astellas.us/docs/AstagrafXL.pdf



Osphena
Marketed by:
Shionogi, Inc
Indication: The FDA has approved Osphena (ospemifene), an estrogen agonist/antagonist, for the treatment of moderate to severe dyspareunia—a symptom of vulvar and vaginal atrophy—due to menopause. The recommended dose of Osphena is 1 tablet orally once daily with food. Osphena should not be used concomitantly with estrogens or estrogen agonist/antagonists, fluconazole, or rifampin.
Dosage Form: Tablets: 60 mg
For More Information: www.osphena.com




Giazo
Marketed by:
Salix Pharmaceuticals, Inc
Indication: The FDA has approved Giazo (balsalazide disodium), a locally acting aminosalicylate, for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years and older. The recommended dose is three 1.1-g tablets 2 times a day (6.6 g/day) with or without food for up to 8 weeks.
Dosage Form: Tablets: 1.1 g
For More Information: www.giazo.com




Sirturo
Marketed by:
Janssen Therapeutics
Indication: The FDA has approved Sirturo (bedaquiline), a diarylquinoline antimycobacterial, for combination therapy in adults 18 years and older with pulmonary multidrug-resistant tuberculosis. The drug is not indicated for the treatment of latent, extrapulmonary, or drug-sensitive tuberculosis. The recommended dose is 400 mg once daily for 2 weeks, followed by 200 mg 3 times per week for 22 weeks. The tablets should be taken with food and swallowed whole with water.
Dosage Form: Tablets: 100 mg
For More Information: www.sirturo.com

Related Articles
Moderate to severe hot flashes and night sweats during menopause are associated with lower bone mineral density and higher hip fracture rates, new research suggests.
Taking another step toward preventing and treating inflammatory bowel disease (IBD), an international team of investigators has determined that the gut bacteria behind Crohn’s disease and ulcerative colitis may be inherited, and antibiotics can make those patients’ gut imbalance worse.
Janssen Research & Development, LLC today announced a collaboration with the International Union Against Tuberculosis and Lung Disease to include SIRTURO® in the STREAM study. The STREAM study is an ongoing, multi-center international randomized controlled trial to evaluate a standardized treatment regimen of anti-tuberculosis drugs for patients with multidrug-resistant tuberculosis.
Current risk assessment strategies for reducing fractures related to osteoporosis among women fail to accurately predict who will experience major osteoporotic injuries.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$